title: Pharmaco-proteomics opportunities for individualizing neurovascular treatment.
abstract: Neurovascular disease often involves multi-organ system injury. For example, patent foramen ovale (PFO) related ischemic strokes involve not just the brain, but also the heart, the lung, and the peripheral vascular circulation. For higher-risk but high-reward systemic therapy (e.g., thrombolytics, therapeutic hypothermia (TH), PFO closure) to be implemented safely, very careful patient selection and close monitoring of disease progression and therapeutic efficacy are imperative. For example, more than a decade after the approval of therapeutic hypothermic and intravenous thrombolysis treatments, they both remain extremely under-utilized, in part due to lack of clinical tools for patient selection or to follow therapeutic efficacy. Therefore, in understanding the complexity of the global effects of clinical neurovascular diseases and their therapies, a systemic approach may offer a unique perspective and provide tools with clinical utility. Clinical proteomic approaches may be promising to monitor systemic changes in complex multi-organ diseases - especially where the disease process can be 'sampled' in clinically accessible fluids such as blood, urine, and CSF. Here, we describe a 'pharmaco-proteomic' approach to three major challenges in translational neurovascular research directly at bedside - in order to better stratify risk, widen therapeutic windows, and explore novel targets to be validated at the bench - (i) thrombolytic treatment for ischemic stroke, (ii) therapeutic hypothermia for post-cardiac arrest syndrome, and (iii) treatment for PFO related paradoxical embolic stroke. In the future, this clinical proteomics approach may help to improve patient selection, ensure more precise clinical phenotyping for clinical trials, and individualize patient treatment.
authors.affiliation: Clinical Proteomics Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. ning@hms.harvard.edu
authors.forename: M M
authors.initials: MM
authors.lastname: Ning
authors.forename: M
authors.initials: M
authors.lastname: Lopez
authors.forename: D
authors.initials: D
authors.lastname: Sarracino
authors.forename: J
authors.initials: J
authors.lastname: Cao
authors.forename: M
authors.initials: M
authors.lastname: Karchin
authors.forename: D
authors.initials: D
authors.lastname: McMullin
authors.forename: X
authors.initials: X
authors.lastname: Wang
authors.forename: F S
authors.initials: FS
authors.lastname: Buonanno
authors.forename: E H
authors.initials: EH
authors.lastname: Lo
mesh_terms: D054316:Biomarkers, Pharmacological / Q000378:metabolism*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D054092:Foramen Ovale, Patent / Q000150:complications / Q000188:drug therapy / Q000601:surgery; D006323:Heart Arrest / Q000628:therapy*; D006801:Humans; D007036:Hypothermia, Induced; D020766:Intracranial Embolism / Q000150:complications / Q000188:drug therapy; D057285:Precision Medicine; D040901:Proteomics; D020521:Stroke / Q000188:drug therapy* / Q000378:metabolism* / Q000517:prevention & control
chemical_list: D054316:Biomarkers, Pharmacological; D005343:Fibrinolytic Agents